Project LAMMA has set out to develop a microfabrication technology that has the potential to disrupt the innovation and production processes of systems at a micro-scale. The technology can be seen as a micro-3D printer capable of reaching a resolution of around 0.2 micron while outperforming most existing technologies by up to 50 times in speed with greater precision and geometric freedom. The technology can potentially be deployed in a wide range of valuable micro-scale products: micro-sensors, bio-scaffolds, micro-lenses, photonic circuits, microfluidics, and metamaterials, which are used by large and rapidly growing industries: production of smartphones, lighting, cameras, data processing centres, cell research, tissue regeneration and artificial organs, point-of-care diagnostics, and drug development.

As part of the scope of this project, the LAMMA technology is being deployed to produce a patented microneedle platform consisting of very precise and specific geometries, designed for drug delivery applications (cosmetics, pain management, cancer therapy, hormonal delivery, and vaccine administration), that may support self-administration, patient compliance, and increased efficacy of drugs through improved self-administration.